Mercado de subcontratación de asuntos regulatorios de IVD en Europa, por servicio (redacción y presentación de documentos regulatorios, registro regulatorio y solicitudes de ensayos clínicos , consultoría regulatoria, representación legal, servicios de gestión de datos, servicios de fabricación y control de productos químicos (CMC) y otros), indicación ( oncología , neurología, cardiología, química clínica e inmunoensayos, medicina de precisión, enfermedades infecciosas, diabetes, pruebas genéticas, VIH/SIDA, hematología, pruebas de medicamentos/farmacogenómica, transfusión de sangre, punto de atención y otros), modo de implementación (nube y en las instalaciones), tamaño de la organización (pequeñas y medianas empresas (PYME) y grandes empresas), etapa (clínica, preclínica y PMA (autorización posterior a la comercialización)), clase (clase I, clase II y clase III), usuario final (compañías farmacéuticas, compañías de dispositivos médicos , compañías de biotecnología y otras), país (Alemania, Francia, Reino Unido, Italia, España, Países Bajos, Suiza, Rusia, Turquía, Bélgica y el resto (Europa) Tendencias de la industria y pronóstico hasta 2029.
Análisis y perspectivas del mercado : mercado de subcontratación de asuntos regulatorios de diagnóstico in vitro en Europa
Se espera que el mercado de subcontratación de asuntos regulatorios de IVD de Europa gane crecimiento de mercado en el período de pronóstico de 2022 a 2029. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 12,8% en el período de pronóstico de 2022 a 2029 y se espera que alcance los USD 527.875,85 mil para 2029.
- Los productos de diagnóstico in vitro son reactivos, dispositivos y sistemas que se utilizan para diagnosticar enfermedades u otras afecciones, incluida la determinación del estado de salud de una persona para curar, mitigar, tratar o prevenir enfermedades. Estos productos están destinados a su uso en la recolección, preparación y examen de muestras del cuerpo humano. Los asuntos regulatorios desempeñan un papel crucial en la industria de dispositivos de diagnóstico in vitro (IVD) y dispositivos médicos. Los servicios de subcontratación de asuntos regulatorios implican la redacción médica y la publicación de documentación regulatoria por parte de profesionales que contribuyen a la producción de documentos de alta calidad para proyectos de investigación clínica. La demanda de subcontratación de servicios regulatorios está aumentando sustancialmente en los estudios clínicos realizados en economías emergentes, lo que proporciona una plataforma saludable para el crecimiento de esta industria.
Los principales factores que impulsan el crecimiento del mercado de subcontratación de asuntos regulatorios de IVD son el aumento de la prevalencia de enfermedades crónicas en toda la región y el avance tecnológico en varios dispositivos de diagnóstico in vitro. El aumento de la adquisición estratégica y la asociación entre organizaciones está creando oportunidades para el crecimiento del mercado. El cambio de las regulaciones con respecto a los dispositivos médicos en diferentes regiones está actuando como la principal restricción para el mercado de subcontratación de asuntos regulatorios de IVD. La falta de infraestructura en el servicio de atención médica está actuando como un desafío importante para el crecimiento del mercado.
Este informe de mercado sobre la subcontratación de asuntos regulatorios de IVD proporciona detalles sobre la participación de mercado, los nuevos desarrollos y el análisis de la cartera de productos, el impacto de los actores del mercado local y nacional, analiza las oportunidades en términos de nuevos segmentos de ingresos, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado, comuníquese con nosotros para obtener un resumen analítico; nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.
Alcance y tamaño del mercado de subcontratación de asuntos regulatorios de diagnóstico in vitro en Europa
El mercado de subcontratación de asuntos regulatorios de IVD en Europa está segmentado en siete segmentos notables que se basan en el servicio, la indicación, el modo de implementación, el tamaño de la organización, la etapa, la clase y el usuario final.
- En cuanto a los servicios, el mercado de externalización de asuntos regulatorios de IVD en Europa se segmenta en redacción y presentación de documentos regulatorios, registro regulatorio y solicitudes de ensayos clínicos, consultoría regulatoria, representación legal, servicios de gestión de datos, servicios de fabricación y control de productos químicos (CMC) y otros. En 2022, se espera que la redacción y presentación de documentos regulatorios domine el mercado, ya que implica la representación legal del producto y, debido a las estrictas regulaciones, que pueden cambiar de un país a otro, implica un alto consumo de recursos debido a la gran demanda de recursos y a los cambios en las políticas.
- Según las indicaciones, el mercado europeo de externalización de asuntos regulatorios de diagnóstico in vitro se segmenta en oncología, neurología, cardiología, química clínica e inmunoensayos, medicina de precisión, enfermedades infecciosas, diabetes, pruebas genéticas, VIH/SIDA, hematología, pruebas de fármacos/farmacogenómica, transfusión de sangre, punto de atención y otros. En 2022, se espera que el segmento de oncología domine, ya que ayuda a mejorar la previsibilidad del proceso de desarrollo de fármacos oncológicos y se convierte en una herramienta importante para el oncólogo en relación con la elección del tratamiento para el paciente.
- En función del modo de implementación, el mercado de externalización de asuntos regulatorios de IVD en Europa se segmenta en la nube y en las instalaciones. En 2022, se espera que el segmento de la nube domine, ya que es rentable y las características flexibles de la solución de la tecnología de computación en la nube en la regulación de IVD brindan una infraestructura estable con el máximo rendimiento para las organizaciones que se ocupan de los sistemas de IVD.
- En función del tamaño de la organización, el mercado de externalización de asuntos regulatorios de IVD en Europa se segmenta en pequeñas y medianas empresas (PYMES) y grandes empresas. En 2022, se espera que el segmento de las grandes empresas domine a medida que la cartera de servicios y tecnología de alta calidad relacionada con la aplicación regulatoria de IVD atraiga una mayor participación de sus pares.
- En función de la etapa, el mercado europeo de externalización de asuntos regulatorios de IVD se segmenta en clínico, preclínico y PMA (autorización posterior a la comercialización). En 2022, se espera que el segmento clínico domine el mercado, ya que los ensayos clínicos realizados en sujetos humanos brindan información sobre el escenario práctico real del equipo. Los ensayos clínicos se llevan a cabo en múltiples fases y es un procedimiento largo que involucra múltiples procedimientos de seguridad y cumplimiento con los organismos reguladores. Esto lo hace costoso y requiere una inversión inicial alta. Como se trata de un proceso obligatorio y conlleva un alto costo, domina el segmento.
- En función de la clase, el mercado europeo de externalización de asuntos regulatorios de diagnóstico in vitro se segmenta en clase I, clase II y clase III. En 2022, se espera que el segmento de clase I domine el mercado, ya que no implica ningún riesgo para la salud pública o un riesgo personal bajo con regulaciones más bajas. Estos tienen una gran demanda y el 47 % de los dispositivos médicos se incluyen en esta categoría.
- En función del usuario final, el mercado europeo de subcontratación de asuntos regulatorios de diagnóstico in vitro se segmenta en empresas farmacéuticas, empresas de dispositivos médicos, empresas de biotecnología y otras. En 2022, se espera que las empresas de dispositivos médicos dominen el mercado, ya que tienen un largo plazo para el desarrollo de dispositivos, que se ve afectado por las regulaciones cambiantes, y este cumplimiento puede llevar mucho tiempo y desperdiciar recursos.
Análisis a nivel de país del mercado de subcontratación de asuntos regulatorios de diagnóstico in vitro en Europa
Se analiza el mercado de subcontratación de asuntos regulatorios de IVD de Europa y se proporciona información sobre el tamaño del mercado por país, servicios, indicación, modo de implementación, tamaño de la organización, etapa, clase y usuario final.
Los países cubiertos en el informe del mercado de subcontratación de asuntos regulatorios de IVD en Europa son Alemania, Francia, Reino Unido, Italia, España, Países Bajos, Suiza, Rusia, Turquía, Bélgica y el resto de Europa.
Alemania domina el mercado debido a los crecientes avances en el sector de la salud y al avance tecnológico en diversos dispositivos de diagnóstico in vitro.
La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como nuevas ventas, ventas de reemplazo, demografía del país, leyes regulatorias y aranceles de importación y exportación son algunos de los principales indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas globales y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los canales de venta se consideran al proporcionar un análisis de pronóstico de los datos del país.
Demanda creciente de subcontratación de asuntos regulatorios de diagnóstico in vitro
El mercado europeo de externalización de asuntos regulatorios de IVD también le proporciona un análisis detallado del mercado para el crecimiento de la industria de cada país con ventas, ventas de componentes, impacto del desarrollo tecnológico en la externalización de asuntos regulatorios de IVD y cambios en los escenarios regulatorios con su apoyo al mercado de externalización de asuntos regulatorios de IVD. Los datos están disponibles para el período histórico de 2012 a 2020.
Análisis del panorama competitivo y de la cuota de mercado de externalización de asuntos regulatorios de diagnóstico in vitro en Europa
El panorama competitivo del mercado de externalización de asuntos regulatorios de diagnóstico in vitro en Europa proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, las líneas de prueba de productos, las aprobaciones de productos, las patentes, la amplitud y la extensión de los productos, el dominio de las aplicaciones y la curva de la línea de vida de la tecnología. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado de externalización de asuntos regulatorios de diagnóstico in vitro en Europa.
Algunos de los principales actores que operan en el mercado de subcontratación de asuntos regulatorios de IVD son Freyr Solutions, PPD Inc. (una subsidiaria de Thremofisher Scientific Inc.), EMERGO, ICON, Parexel International Corporation, CRITERIUM, INC., Groupe ProductLife SA, Labcorp Drug Development, WuXi AppTec, Genpact, Medpace, Dor Pharmaceutical Services, Qserve, entre otros. Los analistas de DBMR comprenden las fortalezas competitivas y brindan un análisis competitivo para cada competidor por separado.
Muchas empresas de todo el mundo también están iniciando desarrollos de productos que también están acelerando el crecimiento del mercado de subcontratación de asuntos regulatorios de IVD en Europa.
Por ejemplo,
- En octubre de 2019, Dor Pharmaceutical Services anunció el lanzamiento de nuevos servicios para la producción de materiales de embalaje y publicidad para productos médicos. Estos servicios cubren todos los aspectos, desde la traducción de los materiales de embalaje y su adaptación a los requisitos del Ministerio de Salud, hasta la preparación gráfica y la impresión de los materiales de embalaje. De esta forma, a través del lanzamiento de este nuevo servicio, la empresa podrá llegar a una nueva base de clientes y los clientes podrán hacer una selección aún más precisa.
- En octubre de 2021, el grupo Propharma adquirió Pharmica Consulting. ProPharma Group, una empresa de cartera de Odyssey Investment Partners, ha adquirido Pharmica Consulting, una empresa de consultoría de ciencias biológicas que ofrece soluciones de consultoría de gestión de proyectos (PM) y software de operaciones patentado a empresas farmacéuticas y biotecnológicas para la ejecución de ensayos clínicos. Esto ha ayudado a la empresa a expandir su negocio a nivel mundial en el mercado.
Las asociaciones, las empresas conjuntas y otras estrategias mejoran la participación de mercado de la empresa con una mayor cobertura y presencia. También brindan a las organizaciones la ventaja de mejorar su oferta de subcontratación de asuntos regulatorios de diagnóstico in vitro mediante una gama más amplia de tamaños.
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 DBMR MARKET POSITION GRID
2.7 VENDOR SHARE ANALYSIS
2.8 MULTIVARIATE MODELING
2.9 SERVICE TIMELINE CURVE
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, REGULATORY SCENARIO
4.1.1 THE U.S.
4.1.2 REGULATIONS IN EUROPE
4.1.3 REGULATIONS IN ASIA
4.1.3.1 CHINA
4.1.3.2 SOUTH KOREA
4.1.3.3 MALAYSIA
4.1.3.4 THAILAND
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISE IN PREVALENCE OF CHRONIC DISEASES ACROSS THE REGION
5.1.2 TECHNOLOGICAL ADVANCEMENT IN DEVELOPING VARIOUS IN VITRO DIAGNOSTIC DEVICES
5.1.3 DEVELOPMENT OF PROJECT-BASED SUPPORT LEADS TO LONG TERM OUTSOURCING AGREEMENT AMONG ORGANIZATION
5.1.4 INCREASE IN PRODUCT REGISTRATION NUMBERS AND CLINICAL TRIAL APPROVALS ACROSS THE REGION
5.2 RESTRAINTS
5.2.1 STRINGENT REGULATIONS REGARDING MEDICAL DEVICES IN DIFFERENT REGIONS
5.2.2 HIGHER COST RELATED TO MAINTENANCE AND OUTSOURCING OF IVD
5.3 OPPORTUNITIES
5.3.1 RISE IN STRATEGIC ACQUISITION & PARTNERSHIP AMONG ORGANIZATION
5.3.2 EMERGENCE OF VARIOUS EFFICIENT TECHNOLOGICAL SERVICES AND STANDARDS
5.3.3 INCREASE IN R&D ACTIVITIES BY COMPANIES ACROSS THE REGION
5.4 CHALLENGES
5.4.1 LACK OF INFRASTRUCTURE IN HEALTHCARE SERVICE
5.4.2 SHORTAGE OF SKILLED PERSONNEL FOR HANDLING IN VITRO DIAGNOSTIC DEVICES
6 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE
6.1 OVERVIEW
6.2 REGULATORY WRITING & SUBMISSIONS
6.3 LEGAL REPRESENTATION
6.4 REGULATORY CONSULTING
6.5 REGULATORY REGISTRATION & CLINICAL TRIAL APPLICATIONS
6.6 CHEMISTRY MANUFACTURING AND CONTROLS (CMC) SERVICES
6.7 DATA MANAGEMENT SERVICES
6.8 OTHERS
7 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY INDICATION
7.1 OVERVIEW
7.2 CLINICAL CHEMISTRY AND IMMUNOASSAYS
7.3 INFECTIOUS DISEASES
7.3.1 VIROLOGY
7.3.2 MICROBIOLOGY AND MYCOLOGY
7.3.3 BACTERIOLOGY
7.3.4 SEPSIS
7.3.5 HEPATITIS B
7.3.6 HEPATITIS C
7.3.7 MALARIA
7.3.8 TUBERCULOSIS
7.3.9 SYPHILIS
7.3.10 HUMAN PAPILLOMAVIRUS (HPV) INFECTION
7.3.11 OTHERS
7.4 HAEMATOLOGY
7.5 DRUG TESTING/PHARMACOGENOMICS
7.6 PRECISION MEDICINE
7.7 DIABETES
7.8 BLOOD TRANSFUSION
7.9 CARDIOLOGY
7.1 POINT OF CARE
7.10.1 WAIVED TEST
7.10.2 AT HOME TESTS
7.11 ONCOLOGY
7.12 NEUROLOGY
7.13 HIV/AIDS
7.14 GENETIC TESTING
7.15 OTHERS
8 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY CLASS
8.1 OVERVIEW
8.2 CLASS I
8.3 CLASS III
8.4 CLASS II
9 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY DEPLOYMENT MODE
9.1 OVERVIEW
9.2 CLOUD
9.3 ON-PREMISES
10 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE
10.1 OVERVIEW
10.2 LARGE ENTERPRISES
10.3 SMALL & MEDIUM ENTERPRISES (SMES)
11 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY STAGE
11.1 OVERVIEW
11.2 CLINICAL
11.3 PRECLINICAL
11.4 PMA (POST MARKET AUTHORIZATION)
12 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY END USER
12.1 OVERVIEW
12.2 MEDICAL DEVICE COMPANIES
12.2.1 BY ORGANIZATION SIZE
12.2.1.1 LARGE ENTERPRISES
12.2.1.2 SMALL & MEDIUM ENTERPRISES (SMES)
12.2.2 BY SERVICE
12.2.2.1 REGULATORY WRITING & SUBMISSIONS
12.2.2.2 LEGAL REPRESENTATION
12.2.2.3 REGULATORY CONSULTING
12.2.2.4 REGULATORY REGISTRATION & CLINICAL TRIAL APPLICATIONS
12.2.2.5 CHEMISTRY MANUFACTURING AND CONTROLS (CMC) SERVICES
12.2.2.6 DATA MANAGEMENT SERVICES
12.2.2.7 OTHERS
12.3 PHARMACEUTICAL COMPANIES
12.3.1 BY ORGANIZATION SIZE
12.3.1.1 LARGE ENTERPRISES
12.3.1.2 SMALL & MEDIUM ENTERPRISES (SMES)
12.3.2 BY SERVICE
12.3.2.1 REGULATORY WRITING & SUBMISSIONS
12.3.2.2 LEGAL REPRESENTATION
12.3.2.3 REGULATORY CONSULTING
12.3.2.4 REGULATORY REGISTRATION & CLINICAL TRIAL APPLICATIONS
12.3.2.5 CHEMISTRY MANUFACTURING AND CONTROLS (CMC) SERVICES
12.3.2.6 DATA MANAGEMENT SERVICES
12.3.2.7 OTHERS
12.4 BIOTECHNOLOGY COMPANIES
12.4.1 BY ORGANIZATION SIZE
12.4.1.1 LARGE ENTERPRISES
12.4.1.2 SMALL & MEDIUM ENTERPRISES (SMES)
12.4.2 BY SERVICE
12.4.2.1 REGULATORY WRITING & SUBMISSIONS
12.4.2.2 LEGAL REPRESENTATION
12.4.2.3 REGULATORY CONSULTING
12.4.2.4 REGULATORY REGISTRATION & CLINICAL TRIAL APPLICATIONS
12.4.2.5 CHEMISTRY MANUFACTURING AND CONTROLS (CMC) SERVICES
12.4.2.6 DATA MANAGEMENT SERVICES
12.4.2.7 OTHERS
12.5 OTHERS
13 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION
13.1 EUROPE
13.1.1 GERMANY
13.1.2 FRANCE
13.1.3 ITALY
13.1.4 SPAIN
13.1.5 U.K.
13.1.6 RUSSIA
13.1.7 TURKEY
13.1.8 SWITZERLAND
13.1.9 BELGIUM
13.1.10 NETHERLANDS
13.1.11 REST OF EUROPE
14 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: EUROPE
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 ICON PLC
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 MEDPACE
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 PAREXEL INTERNATIONAL CORPORATION
16.3.1 COMPANY SNAPSHOT
16.3.2 COMPANY SHARE ANALYSIS
16.3.3 PRODUCT PORTFOLIO
16.3.4 RECENT DEVELOPMENTS
16.4 LABCORP DRUG DEVELOPMENT
16.4.1 COMPANY SNAPSHOT
16.4.2 REVENUE ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 RECENT DEVELOPMENT
16.5 PPD INC. (A SUBSIDIARY OF THERMOFISHER SCIENTIFIC INC.)
16.5.1 COMPANY SNAPSHOT
16.5.2 COMPANY SHARE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENTS
16.6 CHARLES RIVER LABORATORIES
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENTS
16.7 FREYR
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENTS
16.8 ASSENT COMPLIANCE INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 ANDAMAN MEDICAL
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 ASIA ACTUAL
16.10.1 COMPANY SNAPSHOT
16.10.2 SERVICE PORTFOLIO
16.10.3 RECENT DEVELOPMENTS
16.11 AXSOURCE
16.11.1 COMPANY SNAPSHOT
16.11.2 PRODUCT PORTFOLIO
16.11.3 RECENT DEVELOPMENTS
16.12 CRITERIUM, INC.
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 DOR PHARMACEUTICAL SERVICES
16.13.1 COMPANY SNAPSHOT
16.13.2 SERVICE PORTFOLIO
16.13.3 RECENT DEVELOPMENTS
16.14 EMERGO BY UL
16.14.1 COMPANY SNAPSHOT
16.14.2 PRODUCT PORTFOLIO
16.14.3 RECENT DEVELOPMENTS
16.15 GENPACT
16.15.1 COMPANY SNAPSHOT
16.15.2 REVENUE ANALYSIS
16.15.3 PRODUCT PORTFOLIO
16.15.4 RECENT DEVELOPMENTS
16.16 GROUPE PRODUCTLIFE S.A.
16.16.1 COMPANY SNAPSHOT
16.16.2 PRODUCT PORTFOLIO
16.16.3 RECENT DEVELOPMENTS
16.17 LORENZ LIFE SCIENCES GROUP
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENTS
16.18 MAKROCARE
16.18.1 COMPANY SNAPSHOT
16.18.2 PRODUCT PORTFOLIO
16.18.3 RECENT DEVELOPMENTS
16.19 MARACA INTERNATIONAL BVBA
16.19.1 COMPANY SNAPSHOT
16.19.2 SERVICE PORTFOLIO
16.19.3 RECENT DEVELOPMENTS
16.2 MDICONSULTANTS, INC.
16.20.1 COMPANY SNAPSHOT
16.20.2 PRODUCT PORTFOLIO
16.20.3 RECENT DEVELOPMENTS
16.21 PBC BIOMED
16.21.1 COMPANY SNAPSHOT
16.21.2 PRODUCT PORTFOLIO
16.21.3 RECENT DEVELOPMENT
16.22 PROMEDICA INTERNATIONAL, A CALIFORNIA CORPORATION
16.22.1 COMPANY SNAPSHOT
16.22.2 PRODUCT PORTFOLIO
16.22.3 RECENT DEVELOPMENT
16.23 PROPHARMA GROUP
16.23.1 COMPANY SNAPSHOT
16.23.2 PRODUCT PORTFOLIO
16.23.3 RECENT DEVELOPMENTS
16.24 QSERVE
16.24.1 COMPANY SNAPSHOT
16.24.2 SERVICE PORTFOLIO
16.24.3 RECENT DEVELOPMENTS
16.25 REGULATORY COMPLIANCE ASSOCIATES INC.
16.25.1 COMPANY SNAPSHOT
16.25.2 PRODUCT PORTFOLIO
16.25.3 RECENT DEVELOPMENT
16.26 RMQ+
16.26.1 COMPANY SNAPSHOT
16.26.2 PRODUCT PORTFOLIO
16.26.3 RECENT DEVELOPMENT
16.27 SARACA SOLUTIONS PRIVATE LIMITED
16.27.1 COMPANY SNAPSHOT
16.27.2 PRODUCT PORTFOLIO
16.27.3 RECENT DEVELOPMENT
16.28 VCLS
16.28.1 COMPANY SNAPSHOT
16.28.2 PRODUCT PORTFOLIO
16.28.3 RECENT DEVELOPMENTS
16.29 WUXI APPTEC
16.29.1 COMPANY SNAPSHOT
16.29.2 REVENUE ANALYSIS
16.29.3 PRODUCT PORTFOLIO
16.29.4 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
Lista de Tablas
TABLE 1 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 2 EUROPE REGULATORY WRITING & SUBMISSIONS IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 3 EUROPE LEGAL REPRESENTATION IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 4 EUROPE REGULATORY CONSULTING IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 5 EUROPE REGULATORY REGISTRATION & CLINICAL TRIAL APPLICATIONS IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 6 EUROPE CHEMISTRY MANUFACTURING AND CONTROLS (CMC) SERVICES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 7 EUROPE DATA MANAGEMENT SERVICES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY MATERIAL, 2020-2029 (USD THOUSAND)
TABLE 8 EUROPE OTHERS IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 9 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY INDICATION, 2020-2029 (USD THOUSAND)
TABLE 10 EUROPE CLINICAL CHEMISTRY AND IMMUNOASSAYS IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 11 EUROPE INFECTIOUS DISEASES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION,2020-2029 (THOUSAND)
TABLE 12 EUROPE INFECTIOUS DISEASES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 13 EUROPE HAEMATOLOGY IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 14 EUROPE DRUG TESTING/PHARMACOGENOMICS IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 15 EUROPE PRECISION MEDICINE IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 16 EUROPE DIABETES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 17 EUROPE BLOOD TRANSFUSION IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 18 EUROPE CARDIOLOGY IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 19 EUROPE POINT OF CARE IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 20 EUROPE POINT OF CARE IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 21 EUROPE ONCOLOGY IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 22 EUROPE NEUROLOGY IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 23 EUROPE HIV/AIDS IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 24 EUROPE GENETIC TESTING IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 25 EUROPE OTHERS IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 26 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY CLASS, 2020-2029 (USD THOUSAND)
TABLE 27 EUROPE CLASS I IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 28 EUROPE CLASS III IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (THOUSAND)
TABLE 29 EUROPE CLASS II IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 30 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY DEPLOYMENT MODE, 2020-2029 (USD THOUSAND)
TABLE 31 EUROPE CLOUD IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 32 EUROPE ON-PREMISES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 33 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY DEPLOYMENT MODE, 2020-2029 (USD THOUSAND)
TABLE 34 EUROPE LARGE ENTERPRISES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 35 EUROPE SMALL & MEDIUM ENTERPRISES (SMES) IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 36 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY STAGE, 2020-2029 (USD THOUSAND)
TABLE 37 EUROPE CLINICAL IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 38 EUROPE PRECLINICAL IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 39 EUROPE PMA (POST MARKET AUTHORIZATION) IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 40 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 41 EUROPE MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 42 EUROPE MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 43 EUROPE MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 44 EUROPE PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 45 EUROPE PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 46 EUROPE PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 47 EUROPE BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 48 EUROPE BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 49 EUROPE BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 50 EUROPE OTHERS IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY REGION, 2020-2029 (USD THOUSAND)
TABLE 51 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)
TABLE 52 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 53 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY INDICATION, 2020-2029 (USD THOUSAND)
TABLE 54 EUROPE INFECTIOUS DISEASES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 55 EUROPE POINT OF CARE IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 56 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY DEPLOYMENT MODE, 2020-2029 (USD THOUSAND)
TABLE 57 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 58 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY STAGE, 2020-2029 (USD THOUSAND)
TABLE 59 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY CLASS, 2020-2029 (USD THOUSAND)
TABLE 60 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 61 EUROPE MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 62 EUROPE MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 63 EUROPE PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 64 EUROPE PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 65 EUROPE BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 66 EUROPE BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 67 GERMANY IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 68 GERMANY IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY INDICATION, 2020-2029 (USD THOUSAND)
TABLE 69 GERMANY INFECTIOUS DISEASES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 70 GERMANY POINT OF CARE IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 71 GERMANY IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY DEPLOYMENT MODE, 2020-2029 (USD THOUSAND)
TABLE 72 GERMANY IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 73 GERMANY IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY STAGE, 2020-2029 (USD THOUSAND)
TABLE 74 GERMANY IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY CLASS, 2020-2029 (USD THOUSAND)
TABLE 75 GERMANY IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 76 GERMANY MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 77 GERMANY MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 78 GERMANY PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 79 GERMANY PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 80 GERMANY BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 81 GERMANY BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 82 FRANCE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 83 FRANCE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY INDICATION, 2020-2029 (USD THOUSAND)
TABLE 84 FRANCE INFECTIOUS DISEASES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 85 FRANCE POINT OF CARE IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 86 FRANCE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY DEPLOYMENT MODE, 2020-2029 (USD THOUSAND)
TABLE 87 FRANCE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 88 FRANCE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY STAGE, 2020-2029 (USD THOUSAND)
TABLE 89 FRANCE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY CLASS, 2020-2029 (USD THOUSAND)
TABLE 90 FRANCE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 91 FRANCE MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 92 FRANCE MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 93 FRANCE PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 94 FRANCE PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 95 FRANCE BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 96 FRANCE BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 97 ITALY IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 98 ITALY IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY INDICATION, 2020-2029 (USD THOUSAND)
TABLE 99 ITALY INFECTIOUS DISEASES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 100 ITALY POINT OF CARE IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 101 ITALY IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY DEPLOYMENT MODE, 2020-2029 (USD THOUSAND)
TABLE 102 ITALY IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 103 ITALY IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY STAGE, 2020-2029 (USD THOUSAND)
TABLE 104 ITALY IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY CLASS, 2020-2029 (USD THOUSAND)
TABLE 105 ITALY IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 106 ITALY MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 107 ITALY MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 108 ITALY PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 109 ITALY PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 110 ITALY BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 111 ITALY BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 112 SPAIN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 113 SPAIN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY INDICATION, 2020-2029 (USD THOUSAND)
TABLE 114 SPAIN INFECTIOUS DISEASES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 115 SPAIN POINT OF CARE IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 116 SPAIN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY DEPLOYMENT MODE, 2020-2029 (USD THOUSAND)
TABLE 117 SPAIN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 118 SPAIN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY STAGE, 2020-2029 (USD THOUSAND)
TABLE 119 SPAIN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY CLASS, 2020-2029 (USD THOUSAND)
TABLE 120 SPAIN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 121 SPAIN MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 122 SPAIN MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 123 SPAIN PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 124 SPAIN PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 125 SPAIN BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 126 SPAIN BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 127 U.K. IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 128 U.K. IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY INDICATION, 2020-2029 (USD THOUSAND)
TABLE 129 U.K. INFECTIOUS DISEASES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 130 U.K. POINT OF CARE IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 131 U.K. IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY DEPLOYMENT MODE, 2020-2029 (USD THOUSAND)
TABLE 132 U.K. IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 133 U.K. IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY STAGE, 2020-2029 (USD THOUSAND)
TABLE 134 U.K. IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY CLASS, 2020-2029 (USD THOUSAND)
TABLE 135 U.K. IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 136 U.K. MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 137 U.K. MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 138 U.K. PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 139 U.K. PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 140 U.K. BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 141 U.K. BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 142 RUSSIA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 143 RUSSIA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY INDICATION, 2020-2029 (USD THOUSAND)
TABLE 144 RUSSIA INFECTIOUS DISEASES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 145 RUSSIA POINT OF CARE IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 146 RUSSIA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY DEPLOYMENT MODE, 2020-2029 (USD THOUSAND)
TABLE 147 RUSSIA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 148 RUSSIA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY STAGE, 2020-2029 (USD THOUSAND)
TABLE 149 RUSSIA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY CLASS, 2020-2029 (USD THOUSAND)
TABLE 150 RUSSIA IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 151 RUSSIA MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 152 RUSSIA MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 153 RUSSIA PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 154 RUSSIA PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 155 RUSSIA BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 156 RUSSIA BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 157 TURKEY IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 158 TURKEY IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY INDICATION, 2020-2029 (USD THOUSAND)
TABLE 159 TURKEY INFECTIOUS DISEASES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 160 TURKEY POINT OF CARE IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 161 TURKEY IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY DEPLOYMENT MODE, 2020-2029 (USD THOUSAND)
TABLE 162 TURKEY IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 163 TURKEY IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY STAGE, 2020-2029 (USD THOUSAND)
TABLE 164 TURKEY IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY CLASS, 2020-2029 (USD THOUSAND)
TABLE 165 TURKEY IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 166 TURKEY MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 167 TURKEY MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 168 TURKEY PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 169 TURKEY PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 170 TURKEY BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 171 TURKEY BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 172 SWITZERLAND IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 173 SWITZERLAND IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY INDICATION, 2020-2029 (USD THOUSAND)
TABLE 174 SWITZERLAND INFECTIOUS DISEASES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 175 SWITZERLAND POINT OF CARE IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 176 SWITZERLAND IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY DEPLOYMENT MODE, 2020-2029 (USD THOUSAND)
TABLE 177 SWITZERLAND. IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 178 SWITZERLAND IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY STAGE, 2020-2029 (USD THOUSAND)
TABLE 179 SWITZERLAND IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY CLASS, 2020-2029 (USD THOUSAND)
TABLE 180 SWITZERLAND IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 181 SWITZERLAND MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 182 SWITZERLAND MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 183 SWITZERLAND PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 184 SWITZERLAND PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 185 SWITZERLAND BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 186 SWITZERLAND BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 187 BELGIUM IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 188 BELGIUM IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY INDICATION, 2020-2029 (USD THOUSAND)
TABLE 189 BELGIUM INFECTIOUS DISEASES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 190 BELGIUM POINT OF CARE IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 191 BELGIUM IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY DEPLOYMENT MODE, 2020-2029 (USD THOUSAND)
TABLE 192 BELGIUM IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 193 BELGIUM IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY STAGE, 2020-2029 (USD THOUSAND)
TABLE 194 BELGIUM IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY CLASS, 2020-2029 (USD THOUSAND)
TABLE 195 BELGIUM IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 196 BELGIUM MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 197 BELGIUM MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 198 BELGIUM PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 199 BELGIUM PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 200 BELGIUM BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 201 BELGIUM BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 202 NETHERLANDS IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 203 NETHERLANDS IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY INDICATION, 2020-2029 (USD THOUSAND)
TABLE 204 NETHERLANDS INFECTIOUS DISEASES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 205 NETHERLANDS POINT OF CARE IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY TYPE, 2020-2029 (USD THOUSAND)
TABLE 206 NETHERLANDS IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY DEPLOYMENT MODE, 2020-2029 (USD THOUSAND)
TABLE 207 NETHERLANDS IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 208 NETHERLANDS IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY STAGE, 2020-2029 (USD THOUSAND)
TABLE 209 NETHERLANDS IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY CLASS, 2020-2029 (USD THOUSAND)
TABLE 210 NETHERLANDS IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY END USER, 2020-2029 (USD THOUSAND)
TABLE 211 NETHERLANDS MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 212 NETHERLANDS MEDICAL DEVICE COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 213 NETHERLANDS PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 214 NETHERLANDS PHARMACEUTICAL COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 215 NETHERLANDS BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY ORGANIZATION SIZE, 2020-2029 (USD THOUSAND)
TABLE 216 NETHERLANDS BIOTECHNOLOGY COMPANIES IN IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
TABLE 217 REST OF EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET, BY SERVICE, 2020-2029 (USD THOUSAND)
Lista de figuras
FIGURE 1 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: SEGMENTATION
FIGURE 2 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: DROC ANALYSIS
FIGURE 4 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: DBMR MARKET POSITION GRID
FIGURE 8 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: END USER COVERAGE GRID
FIGURE 10 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: SEGMENTATION
FIGURE 11 RISE IN THE PREVALENCE OF CHRONIC DISEASES ACROSS IS EXPECTED TO DRIVE EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 SERVICE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET IN 2022 & 2029
FIGURE 13 ASIA-PACIFIC IS EXPECTED TO DOMINATE AND IS THE FASTEST GROWING REGION IN THE EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FOR EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET
FIGURE 15 MULTIPLE CHRONIC CONDITIONS AMONG PEOPLE AGED 65 AND ABOVE IN EUROPEAN REGION (2017)
FIGURE 16 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: BY SERVICE, 2021
FIGURE 17 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: BY INDICATION, 2021
FIGURE 18 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: BY CLASS, 2021
FIGURE 19 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: BY DEPLOYMENT MODE, 2021
FIGURE 20 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: BY ORGANIZATION SIZE, 2021
FIGURE 21 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: BY STAGE, 2021
FIGURE 22 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: BY END USER, 2021
FIGURE 23 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: SNAPSHOT (2021)
FIGURE 24 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: BY COUNTRY (2021)
FIGURE 25 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: BY COUNTRY (2022 & 2029)
FIGURE 26 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: BY COUNTRY (2021 & 2029)
FIGURE 27 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: BY SERVICE (2022-2029)
FIGURE 28 EUROPE IVD REGULATORY AFFAIRS OUTSOURCING MARKET: COMPANY SHARE 2021 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
